CIRM Funded Clinical Trials

Phase 1/1b study of T-allo10 infusion after HLA-partially matched abdepleted-HSCT in children and young adults with hematologic malignancies.

Disease Area:

B cell cancers, Leukemia, Leukemia, Acute Myeloid (AML)

Investigator:

Dr. Matthew H Porteus

Institution:

Stanford University

CIRM Grant:

CLIN2-12563 (Active)

Award Value:

$10,563,822.00

Trial Sponsor:

Stanford University

Trial Stage:

Phase 1

Trial Status:

Recruiting

Targeted Enrollment:

22

ClinicalTrials.gov ID:

NCT04640987

Details:

Dr. Matthew H Porteus and his team at Stanford will test an immunotherapy cell approach using a therapy that is enriched with specialized immune cells called type I regulatory T (Tr1) cells. These cells will be infused into the patient following the bone marrow transplant. Both the Tr1 cells and the bone marrow will come from the same donor. The hope is this will help provide the patient’s immune system with these regulatory cells to combat life-threatening graft versus host disease and increase the success of treatment and bone marrow (HSCT) transplant.